In patients without pre-existing CAD, the risk of myocardial infarction with triptans is:

Prepare for the Pharmacology IV – Headache Therapeutics Test. Review the therapeutic approaches, tackle multiple-choice questions with explanations, and boost your test-taking confidence. Ace your exam with precision!

Main concept: Triptans can cause coronary vasoconstriction, so their cardiovascular safety depends on the patient’s baseline heart health. In people with no pre-existing coronary disease, the chance of a triptan triggering a myocardial infarction is extremely small because normal coronary arteries tolerate the drug’s vasoconstrictive effect and there are no significant atherosclerotic risks to amplify it.

That’s why the best answer is very low. It reflects the overall clinical understanding that, while triptans can cause vasoconstriction and are contraindicated in ischemic heart disease, in individuals without CAD the risk of an MI is minimal. In contrast, the risk is higher for those with known CAD or substantial cardiovascular risk factors, which is why caution or avoidance is advised in those patients.